deltatrials
Completed PHASE3 NCT00088465

Open-Label Study of Intramuscular Olanzapine Depot in Patients With Schizophrenia or Schizoaffective Disorder

An Open-Label Study of Intramuscular Olanzapine Depot in Patients With Schizophrenia or Schizoaffective Disorder

Sponsor: Eli Lilly and Company

Conditions Schizoaffective Disorder Schizophrenic Disorders
Interventions Intramuscular olanzapine depot
Updated 7 times since 2017 Last updated: Dec 9, 2011 Started: Aug 31, 2004 Primary completion: Dec 31, 2010 Completion: Dec 31, 2010

A PHASE3 clinical study on Schizoaffective Disorder and Schizophrenic Disorders, this trial is completed. The trial is conducted by Eli Lilly and Company and has accumulated 7 data snapshots since 2004. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Change History

7 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

▶ Show 2 earlier versions

  1. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE3

  2. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE3

    First recorded

Aug 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Eli Lilly and Company
Data source: Eli Lilly and Company

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albuquerque, United States, Aparecida de Goiânia, Brazil, Bad Saarow, Germany, Barcelona, Spain, Bayonne, France, Beer Yaacov, Israel, Berlin, Germany, Bourg-en-Bresse, France, Bradenton, United States, Braga, Portugal and 82 more location s